This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HIV/AIDS	CD36 (GPIV)	<p><i>In vitro</i> studies suggest anti-CD36 antibodies could help treat HIV. In HIV-infected macrophages, an anti-CD36 mAb or siRNA decreased the release of HIV p24 from the macrophages, which facilitates the spread of the virus, compared with an isotype mAb or control siRNA. In HIV-infected macrophages cocultured with T cells, the anti-CD36 antibody decreased the fraction of infected T cells compared with isotype mAb. Next steps include identifying a humanized antibody against CD36.</p> <p>Arteria S.A. has the CD36 inhibitor AP-5258 in preclinical testing to treat dyslipidemia.</p> <p>SciBX 6(47); doi:10.1038/scibx.2013.1355 Published online Dec. 12, 2013</p>	Patent application filed; licensing status unavailable	<p>Berre, S. <i>et al. J. Exp. Med.</i>; published online Oct. 21, 2013; doi:10.1084/jem.20130566 Contact: Philippe Benaroch, Curie Institute, Paris, France e-mail: benaroch@curie.fr</p>